Resonance Health Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Andrew Harrison

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	7.5yrs

Recent management updates

Recent updates

CEO

Andrew Harrison (52 yo)

less than a year

Tenure

Mr. Andrew Duncan Harrison, BCom (Hons), MAICD was the Managing Director and Chief Executive Officer of Capitol Health Limited since November 11, 2016 until June 30, 2019. He serves as Chief Executive Offi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mitchell Wells	Company Secretary & Non Executive Director	2.1yrs	AU$322.88k	0.36% A$ 124.0k
Andrew Harrison	Chief Executive Officer	less than a year	no data	no data
Benjamin Carruthers	Chief Financial Officer	less than a year	no data	no data
Liesl Ellies	General Counsel	no data	no data	no data
Chad Tondut	Communications Manager and GM of Products & Portfolio	no data	no data	no data
Ajay Nair	General Manager of Global Sales & Marketing	no data	no data	no data
Timothy St. Pierre	Chief Research Scientist	no data	AU$206.94k	no data
Wenjie Pang	Chief Scientific Officer – Imaging & AI	no data	no data	no data
Sherif Boulos	Chief Scientific Officer of Molecular	no data	no data	no data

0.8yrs

Average Tenure

Experienced Management: RHT's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mitchell Wells	Company Secretary & Non Executive Director	6.3yrs	AU$322.88k	0.36% A$ 124.0k
Simon Panton	Non-Executive Director	14.6yrs	AU$40.00k	16.75% A$ 5.8m
Travis Baroni	Independent Non-Executive Director	7.5yrs	AU$40.00k	0.21% A$ 73.9k
Martin Peter Blake	Independent Non-Executive Chairman	16.6yrs	AU$60.00k	1.45% A$ 497.8k
Aaron Brinkworth	Non-Executive and Independent Director	1.2yrs	AU$11.64k	0.067% A$ 23.1k

7.5yrs

Average Tenure

Experienced Board: RHT's board of directors are considered experienced (7.5 years average tenure).

Resonance Health Management

Management criteria checks 1/4

Key information

Recent management updates

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Recent updates

Resonance Health Limited, Annual General Meeting, Nov 16, 2023

Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023

Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022)

Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ

Insufficient new directors

Resonance Health Limited, Annual General Meeting, Nov 24, 2022

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2021)

FerriScan Now Available on 3 Tesla (3T) MRI Machines

Resonance Health Limited Appoints Liesl Ellies as Joint Company Secretary

Insufficient new directors

Resonance Health Limited Receives United States CPT Code Confirmation for Liversmart

Resonance Health Limited Announces US FDA Clearance for LiverSmart

Resonance Health Ltd Provides Update on its Antisense Oligonucleotide Project for Treating Viral Hepatitis

Resonance Health Limited Announces Filing of Two Patent Applications

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Resonance Health Ltd announces R&D Molecular Medicine ASON Project Results of Dosing Study

Full year 2021 earnings released: EPS AU$0.001 (vs AU$0.002 loss in FY 2020)

Chief Executive Officer Alison Laws has left the company

Resonance Health Limited Announces Filing of Patent Application

Resonance Health Limited Provides Update on Its Antisense Oligonucleotide R&D Project for Treating Liver Related Diseases

Resonance Health Ltd HepaFat-AI Receives CE Marking

Resonance Health Ltd Receives Australian Therapeutic Goods Administration Approval for HepaFat-AI

Resonance's HepaFat-AI Incorporated into Blackford Analysis

New 90-day high: AU$0.28

Resonance Health Ltd Develops New Artificial Intelligence Tool for the Automated Review of Chest Computed Tomography Scans of Patients with Suspected Pulmonary Embolism

Full year earnings released - AU$0.0017 loss per share

Full year earnings released - AU$0.0017 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure